NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Natera, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$399.42+5.98 (+1.52%)
Close on Oct 19, 2026
- Market cap
- $57.23B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
95.2%
137M of 144M shares
Institutional holders
846
157 new, 66 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 474 sales
Net sold $374.70M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 9,021,825 | 6.30% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 7,565,936 | 5.60% | 13G (passive) amendment | Mar 31, 2025 |
| Vanguard Capital Management | 7,205,939 | 5.08% | 13G (passive) | Mar 31, 2026 |
| JPMorgan Chase & Co. | 12,825,640 | 9.10% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NTRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 12,865,346 | 8.93% | $3.51B | −521,321 | 0.19% |
| BlackRock, Inc. | 10,914,608 | 7.57% | $2.96B | +237,270 | 0.04% |
| Price T Rowe Associates Inc /Md/ | 9,021,895 | 6.26% | $2.45M | −3,162,981 | 0.25% |
| Vanguard Capital Management LLC | 6,228,216 | 4.32% | $1.69B | +219,720 | 0.04% |
| Vanguard Portfolio Management LLC | 5,782,640 | 4.01% | $1.57B | +137,945 | 0.07% |
| FMR LLC | 5,451,396 | 3.78% | $1.48B | +2,897,142 | 0.06% |
| Wellington Management Group Llp | 4,040,738 | 2.80% | $1.10B | −727,855 | 0.19% |
| State Street Corp | 3,655,618 | 2.54% | $992.32M | +238,146 | 0.03% |
| Duquesne Family Office LLC | 3,186,306 | 2.21% | $864.92K | +122,700 | 16.60% |
| Geode Capital Management, LLC | 2,750,013 | 1.91% | $744.57M | −25,915 | 0.04% |
| Franklin Resources Inc | 2,725,903 | 1.89% | $739.95M | +240,578 | 0.16% |
| Castle Hook Partners LP | 2,596,276 | 1.80% | $704.76M | +66,466 | 3.23% |
| Coatue Management LLC | 2,505,090 | 1.74% | $680.01M | −36,752 | 1.40% |
| Aqr Capital Management LLC | 2,344,570 | 1.63% | $628.09M | +70,579 | 0.22% |
| Farallon Capital Management LLC | 2,218,366 | 1.54% | $602.18M | −989,000 | 2.78% |
| Massachusetts Financial Services Co /Ma/ | 1,971,391 | 1.37% | $535.08M | −68,715 | 0.17% |
| Norges Bank | 1,828,122 | 1.27% | $496.24M | New | 0.05% |
| Fred Alger Management, LLC | 1,778,009 | 1.23% | $482.64M | +21,537 | 1.61% |
| Goldman Sachs Group Inc | 1,720,152 | 1.19% | $466.94M | +952,921 | 0.04% |
| Sofinnova Investments, Inc. | 1,550,280 | 1.08% | $420.82M | – | 21.76% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 846 | 137M | 95.2% | 157 / 356 | 242 / 66 | 15M | 12M |
| Q1 2026 | 766 | 134M | 93.2% | 98 / 301 | 265 / 106 | 23M | 9M |
| Q4 2025 | 785 | 133M | 92.5% | 185 / 277 | 241 / 63 | 16M | 24M |
| Q3 2025 | 686 | 142M | 98.5% | 111 / 269 | 230 / 65 | 22M | 11M |
| Q2 2025 | 648 | 132M | 91.5% | 110 / 272 | 197 / 55 | 16M | 14M |
| Q1 2025 | 597 | 130M | 90.4% | 116 / 238 | 192 / 103 | 18M | 12M |
| Q4 2024 | 596 | 125M | 86.7% | 146 / 185 | 211 / 37 | 15M | 16M |
| Q3 2024 | 495 | 126M | 87.6% | 68 / 180 | 195 / 42 | 21M | 17M |
| Q2 2024 | 475 | 129M | 89.4% | 96 / 184 | 147 / 29 | 15M | 16M |
| Q1 2024 | 411 | 131M | 90.7% | 96 / 145 | 135 / 34 | 20M | 13M |
| Q4 2023 | 351 | 124M | 86.0% | 67 / 129 | 127 / 32 | 23M | 14M |
| Q3 2023 | 319 | 115M | 79.6% | 43 / 113 | 120 / 38 | 14M | 8M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NTRA | Value | % of fund | As of |
|---|---|---|---|---|---|
| JPMorgan Large Cap Growth Fund | 5,550,940 | 3.85% | $1.51B | 1.24% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,320,351 | 3.00% | $1.17B | 0.05% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,119,416 | 2.16% | $846.77M | 0.45% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,799,359 | 1.25% | $488.44M | 1.04% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,642,271 | 1.14% | $445.79M | 0.46% | Jun 30, 2026 |
| Fidelity Contrafund | 1,617,222 | 1.12% | $438.99M | 0.24% | Jun 30, 2026 |
| Franklin Dynatech Fund | 1,450,000 | 1.01% | $393.60M | 1.30% | Jun 30, 2026 |
| MFS Mid Cap Growth Fund | 1,345,572 | 0.93% | $300.56M | 2.18% | May 31, 2026 |
| Growth Fund of America | 988,724 | 0.69% | $220.85M | 0.06% | May 31, 2026 |
| iShares Biotechnology ETF | 967,683 | 0.67% | $262.68M | 2.89% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 817,775 | 0.57% | $221.99M | 1.51% | Jun 30, 2026 |
| iShares Russell Mid-Cap Growth ETF | 805,893 | 0.56% | $218.76M | 1.01% | Jun 30, 2026 |
| T. Rowe Price Large-Cap Growth Fund | 800,499 | 0.56% | $217.30M | 1.06% | Jun 30, 2026 |
| Vanguard U.S. Growth Fund | 783,620 | 0.54% | $175.04M | 0.37% | May 31, 2026 |
| JPMorgan Mid Cap Growth Fund | 781,556 | 0.54% | $212.15M | 1.60% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Matthew Rabinowitz | EXECUTIVE CHAIRMAN, Director | 2,125,394 | 1.47% | Sep 16, 2026 |
| Steven Leonard Chapman | CEO AND PRESIDENT, Director | 98,199 | 0.07% | Sep 3, 2026 |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 109,914 | 0.08% | Sep 18, 2026 |
| John Fesko | PRESIDENT, CHIEF BUS. OFFICER | 197,257 | 0.14% | Aug 28, 2026 |
| Daniel Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 170,073 | 0.12% | Aug 5, 2026 |
| Michael Burkes Brophy | CHIEF FINANCIAL OFFICER | 51,637 | 0.04% | Aug 5, 2026 |
| Jonathan Sheena | Director | 241,744 | 0.17% | Sep 25, 2026 |
| Rowan E. Chapman | Director | 4,663 | 0.00% | Jul 17, 2026 |
| Eric H. Rubin | Director | 2,204 | 0.00% | Jun 30, 2026 |
| Roelof Botha | Director | 1,080,663 | 0.75% | Jun 30, 2026 |
| Roy D. Baynes | Director | 20,083 | 0.01% | Jun 30, 2026 |
| Thomas J. Lynch Jr. | Director | 1,905 | 0.00% | Jun 30, 2026 |
| Herm Rosenman | Director | 5,821 | 0.00% | Jun 30, 2026 |
| Gail Boxer Marcus | Director | 7,852 | 0.01% | Jun 30, 2026 |
| Monica Bertagnolli | Director | 6,945 | 0.00% | Jun 30, 2026 |
| Brinkley Ruth Williams | Director | 5,475 | 0.00% | Apr 28, 2026 |
| James Healy | Director | 1,596,540 | 1.11% | Apr 29, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jonathan Sheena Director | Sep 23, 2026 | Sale(10b5-1 plan) | −1,293 | $388.71 | $502.60K | 11,430 |
| Jonathan Sheena Director | Sep 23, 2026 | Sale(10b5-1 plan) | −2,734 | $387.65 | $1.06M | 12,723 |
| Jonathan Sheena Director | Sep 23, 2026 | Sale(10b5-1 plan) | −2,320 | $389.69 | $904.08K | 9,110 |
| Jonathan Sheena Director | Sep 23, 2026 | Sale(10b5-1 plan) | −110 | $390.42 | $42.95K | 9,000 |
| Jonathan Sheena Director | Sep 23, 2026 | Sale(10b5-1 plan) | −2,175 | $386.71 | $841.09K | 15,457 |
| Jonathan Sheena Director | Sep 23, 2026 | Sale(10b5-1 plan) | −400 | $385.10 | $154.04K | 17,632 |
| Jonathan Sheena Director | Sep 23, 2026 | Sale(10b5-1 plan) | −220 | $390.53 | $85.92K | 9,000 |
| Jonathan Sheena Director | Sep 23, 2026 | Sale(10b5-1 plan) | −1,935 | $389.71 | $754.09K | 9,220 |
| Jonathan Sheena Director | Sep 23, 2026 | Sale(10b5-1 plan) | −1,341 | $388.76 | $521.33K | 11,155 |
| Jonathan Sheena Director | Sep 23, 2026 | Sale(10b5-1 plan) | −2,846 | $387.74 | $1.10M | 12,496 |
| Jonathan Sheena Director | Sep 23, 2026 | Sale(10b5-1 plan) | −2,300 | $386.64 | $889.27K | 15,342 |
| Jonathan Sheena Director | Sep 23, 2026 | Sale(10b5-1 plan) | −390 | $385.29 | $150.26K | 17,642 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Sep 16, 2026 | Gift | −945 | – | – | 109,914 |
| Jonathan Sheena Director | Sep 16, 2026 | Sale(10b5-1 plan) | −100 | $349.05 | $34.91K | 224,164 |
| Jonathan Sheena Director | Sep 16, 2026 | Sale(10b5-1 plan) | −1,400 | $353.83 | $495.36K | 222,764 |
| Jonathan Sheena Director | Sep 16, 2026 | Sale(10b5-1 plan) | −450 | $354.91 | $159.71K | 222,314 |
| Jonathan Sheena Director | Sep 16, 2026 | Sale(10b5-1 plan) | −800 | $355.95 | $284.76K | 221,514 |
| Jonathan Sheena Director | Sep 16, 2026 | Sale(10b5-1 plan) | −200 | $356.87 | $71.37K | 221,314 |
| Jonathan Sheena Director | Sep 16, 2026 | Sale(10b5-1 plan) | −200 | $348.03 | $69.61K | 224,264 |
| Jonathan Sheena Director | Sep 15, 2026 | Sale(10b5-1 plan) | −6,000 | $350.07 | $2.10M | 224,464 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −2,000 | $350.01 | $700.02K | 0 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −800 | $351.25 | $281.00K | 2,125,394 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −14,500 | $350.81 | $5.09M | 2,126,194 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −4,206 | $349.51 | $1.47M | 2,140,694 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −8,094 | $348.65 | $2.82M | 2,144,900 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −2,700 | $347.81 | $939.09K | 2,152,994 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −1,122 | $346.68 | $388.97K | 2,155,694 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −2,700 | $345.38 | $932.53K | 2,156,816 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −5,839 | $344.49 | $2.01M | 2,159,516 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −2,240 | $343.56 | $769.57K | 2,165,355 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −1,956 | $342.18 | $669.30K | 2,167,595 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −1,813 | $341.41 | $618.98K | 2,169,551 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −2,549 | $340.25 | $867.30K | 2,171,364 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −1,481 | $339.24 | $502.41K | 2,173,913 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −6,206 | $330.05 | $2.05M | 2,211,636 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −6,015 | $329.12 | $1.98M | 2,217,842 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −1,537 | $328.09 | $504.27K | 2,223,857 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −3,494 | $330.98 | $1.16M | 2,208,142 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −1,000 | $332.02 | $332.02K | 2,207,142 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −2,246 | $333.07 | $748.08K | 2,204,896 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −2,818 | $334.24 | $941.89K | 2,202,078 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −4,064 | $342.51 | $1.39M | 2,175,394 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −2,700 | $341.35 | $921.65K | 2,179,458 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −2,000 | $340.31 | $680.62K | 2,182,158 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −2,100 | $339.37 | $712.68K | 2,184,158 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −1,400 | $338.30 | $473.62K | 2,186,258 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −2,207 | $337.17 | $744.13K | 2,187,658 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −8,459 | $336.27 | $2.84M | 2,189,865 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −3,754 | $335.18 | $1.26M | 2,198,324 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −1,300 | $329.62 | $428.51K | 2,225,394 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −800 | $325.01 | $260.01K | 2,274,594 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −3,647 | $326.11 | $1.19M | 2,270,947 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −10,556 | $327.14 | $3.45M | 2,260,391 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −17,933 | $327.97 | $5.88M | 2,242,458 |
| Matthew Rabinowitz EXECUTIVE CHAIRMAN, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −15,764 | $328.95 | $5.19M | 2,226,694 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Sep 2, 2026 | Sale(10b5-1 plan) | −15,160 | $326.89 | $4.96M | 110,859 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Sep 1, 2026 | Sale(10b5-1 plan) | −1,000 | $319.76 | $319.76K | 128,019 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Sep 1, 2026 | Sale(10b5-1 plan) | −600 | $321.91 | $193.15K | 126,019 |
| Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | Sep 1, 2026 | Sale(10b5-1 plan) | −1,400 | $320.92 | $449.29K | 126,619 |
| Steven Leonard Chapman CEO AND PRESIDENT, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −1,698 | $320.99 | $545.04K | 98,199 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Rabinowitz Matthew Director, Officer | Oct 15, 2026 | 50,000 | $19.74M | Oct 15, 2026 | Previously Exercised Stock Options |
| Moshkevich Solomon Officer | Oct 1, 2026 | 3,000 | $1.24M | Oct 1, 2026 | Restricted Stock |
| L. Chapman Steven Officer, Director | Oct 1, 2026 | 1,273 | $526.14K | Oct 1, 2026 | Restricted Stock |
| Jonathan Sheena Director | Sep 23, 2026 | 21,064 | $8.16M | Sep 23, 2026 | FOUNDERS SHARES |
| Ii Tr U/A Dtd 10/22/2021 Tinkerbelle Officer, Director | Sep 15, 2026 | 2,000 | $700.01K | Sep 15, 2026 | Gift from Affiliate |
| Rabinowitz Matthew Director, Officer | Sep 11, 2026 | 200,000 | $65.23M | Sep 11, 2026 | Previously Exercised Stock Options |
| Moshkevich Solomon OFFICER | Sep 2, 2026 | 0 | $0 | Sep 2, 2026 | Restricted Stock Units |
| Moshkevich Solomon Officer | Sep 1, 2026 | 3,000 | $962.19K | Sep 1, 2026 | Performance and Restricted Stock |
| L. Chapman Steven Officer, Director | Sep 1, 2026 | 1,698 | $545.04K | Sep 1, 2026 | Restricted Stock |
| Jonathan Sheena Director | Aug 7, 2026 | 18,000 | $5.95M | Aug 7, 2026 | ISO STOCK OPTIONS |
| Ii Tr U/A Dtd 10/22/2021 Tinkerbelle Officer, Director | Aug 7, 2026 | 2,000 | $641.80K | Aug 7, 2026 | Gift from Affiliate |
| Brophy Michael Officer | Aug 4, 2026 | 478 | $129.23K | Aug 4, 2026 | Restricted Stock Units |
| Moshkevich Solomon Officer | Aug 3, 2026 | 3,000 | $795.75K | Aug 3, 2026 | Performance Shares |
| L. Chapman Steven Officer, Director | Aug 3, 2026 | 1,894 | $502.67K | Aug 3, 2026 | Restricted Stock |
| Brophy Michael OFFICER | Aug 3, 2026 | 313 | $83.81K | Aug 3, 2026 | Restricted Stock Units |